StockNews.com Downgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Monday.

Several other brokerages have also recently commented on PBH. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research report on Monday, December 9th. DA Davidson reiterated a “buy” rating and set a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Hold” and an average target price of $85.25.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH traded down $1.07 on Monday, hitting $77.38. 143,387 shares of the company were exchanged, compared to its average volume of 251,466. The company’s 50 day moving average price is $80.08 and its two-hundred day moving average price is $73.71. The firm has a market capitalization of $3.82 billion, a price-to-earnings ratio of 18.83, a PEG ratio of 2.32 and a beta of 0.49. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare has a one year low of $57.95 and a one year high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The company’s quarterly revenue was down .9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.07 earnings per share. Research analysts expect that Prestige Consumer Healthcare will post 4.44 earnings per share for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. The trade was a 30.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mary Beth Fritz sold 9,885 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now directly owns 18,835 shares of the company’s stock, valued at approximately $1,543,904.95. This trade represents a 34.42 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 38,810 shares of company stock valued at $3,187,300. 1.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Victory Capital Management Inc. increased its position in shares of Prestige Consumer Healthcare by 9.0% during the 2nd quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after purchasing an additional 171,357 shares during the last quarter. Arizona State Retirement System increased its holdings in Prestige Consumer Healthcare by 1.9% during the second quarter. Arizona State Retirement System now owns 13,900 shares of the company’s stock worth $957,000 after buying an additional 264 shares during the last quarter. Norden Group LLC raised its position in Prestige Consumer Healthcare by 25.9% during the second quarter. Norden Group LLC now owns 12,435 shares of the company’s stock worth $856,000 after acquiring an additional 2,559 shares in the last quarter. Quest Partners LLC lifted its stake in Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after acquiring an additional 424 shares during the last quarter. Finally, Choreo LLC acquired a new stake in Prestige Consumer Healthcare in the second quarter valued at $677,000. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.